The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence

被引：4

作者：

Liu, Youjun ^{[1
]}

Chen, Huanshi ^{[1
]}

Chen, Tong ^{[1
]}

Qiu, Guowen ^{[1
]}

Han, Yu ^{[2
]}

机构：

[1] Liuzhou Municipal Liutie Cent Hosp, Dept Spinal Surg, Liuzhou, Peoples R China

[2] Zhengzhou Univ, Dept Orthoped, Affiliated Hosp 1, Zhengzhou, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

osteoclasts; bone metastasis; antiresorptive drugs; therapeutic targets; targeted therapy; BREAST-CANCER PATIENTS; ADJUVANT ZOLEDRONIC ACID; PLACEBO-CONTROLLED TRIAL; SKELETAL-RELATED EVENTS; ORAL SODIUM CLODRONATE; PHASE-III TRIAL; DOUBLE-BLIND; CATHEPSIN-K; SRC KINASE; OPEN-LABEL;

D O I：

10.3389/fonc.2024.1445025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The occurrence of bone metastasis is a grave medical concern that substantially impacts the quality of life in patients with cancer. The precise mechanisms underlying bone metastasis remain unclear despite extensive research efforts, and efficacious therapeutic interventions are currently lacking. The ability of osteoclasts to degrade the bone matrix makes them a crucial factor in the development of bone metastasis. Osteoclasts are implicated in several aspects of bone metastasis, encompassing the formation of premetastatic microenvironment, suppression of the immune system, and reactivation of quiescent tumor cells. Contemporary clinical interventions targeting osteoclasts have proven effective in mitigating bone-related symptoms in patients with cancer. This review comprehensively analyzes the mechanistic involvement of osteoclasts in bone metastasis, delineates potential therapeutic targets associated with osteoclasts, and explores clinical evidence regarding interventions targeting osteoclasts.

引用

页数：16

共 162 条

[1] Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin [J].

Abdelaziz, Dareen M. ;

Stone, Laura S. ;

Komarova, Svetlana V. .

BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (02) :227-237

[2] Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers [J].

Alzahrani, Mashari ;

Stober, Carol ;

Liu, Michelle ;

Awan, Arif ;

Ng, Terry L. ;

Pond, Gregory ;

Alshamsan, Bader ;

Vandermeer, Lisa ;

Clemons, Mark .

SUPPORTIVE CARE IN CANCER, 2022, 30 (05) :3977-3984

[3] Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication [J].

An, Gang ;

Acharya, Chirag ;

Feng, Xiaoyan ;

Wen, Kenneth ;

Zhong, Mike ;

Zhang, Li ;

Munshi, Nikhil C. ;

Qiu, Lugui ;

Tai, Yu-Tzu ;

Anderson, Kenneth C. .

BLOOD, 2016, 128 (12) :1590-1603

[4] RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis [J].

Andrade, Kelsi ;

Fornetti, Jaime ;

Zhao, Ling ;

Miller, Scott C. ;

Randall, R. Lor ;

Anderson, Neysi ;

Waltz, Susan E. ;

McHale, Mark ;

Welm, Alana L. .

SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (374) :1-+

[5] A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer [J].

Antonarakis, Emmanuel S. ;

Heath, Elisabeth I. ;

Posadas, Edwin M. ;

Yu, Evan Y. ;

Harrison, Michael R. ;

Bruce, Justine Y. ;

Cho, Steve Y. ;

Wilding, Gregory E. ;

Fetterly, Gerald J. ;

Hangauer, David G. ;

Kwan, Min-Fun R. ;

Dyster, Lyn M. ;

Carducci, Michael A. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) :883-892

[6] Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial [J].

Araujo, John C. ;

Trudel, Geralyn C. ;

Saad, Fred ;

Armstrong, Andrew J. ;

Yu, Evan Y. ;

Bellmunt, Joaquim ;

Wilding, George ;

McCaffrey, John ;

Serrano, Sergio V. ;

Matveev, Vsevolod B. ;

Efstathiou, Eleni ;

Oudard, Stephane ;

Morris, Michael J. ;

Sizer, Bruce ;

Goebell, Peter J. ;

Heidenreich, Axel ;

de Bono, Johann S. ;

Begbie, Stephen ;

Hong, Jun H. ;

Richardet, Eduardo ;

Gallardo, Enrique ;

Paliwal, Prashni ;

Durham, Susan ;

Cheng, Shinta ;

Logothetis, Christopher J. .

LANCET ONCOLOGY, 2013, 14 (13) :1307-1316

[7] Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice [J].

Arellano, Danna L. ;

Juarez, Patricia ;

Verdugo-Meza, Andrea ;

Almeida-Luna, Paloma S. ;

Corral-Avila, Juan A. ;

Drescher, Florian ;

Olvera, Felipe ;

Jimenez, Samanta ;

Elzey, Bennett D. ;

Guise, Theresa A. ;

Fournier, Pierrick G. J. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (08) :1446-1463

[8] Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone [J].

Asano, Tatsuo ;

Okamoto, Kazuo ;

Nakai, Yuta ;

Tsutsumi, Masanori ;

Muro, Ryunosuke ;

Suematsu, Ayako ;

Hashimoto, Kyoko ;

Okamura, Tadashi ;

Ehata, Shogo ;

Nitta, Takeshi ;

Takayanagi, Hiroshi .

NATURE METABOLISM, 2019, 1 (09) :868-875

[9] Increase in the Number of Bone Marrow Osteoclast Precursors at Different Skeletal Sites, Particularly in Long Bone and Jaw Marrow in Mice Lacking IL-1RA [J].

Ascone, Giuliana ;

Cao, Yixuan ;

Jansen, Ineke D. C. ;

Di Ceglie, Irene ;

van den Bosch, Martijn H. J. ;

Blom, Arjen B. ;

van Lent, Peter L. E. M. ;

Everts, Vincent ;

de Vries, Teun J. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11) :1-16

[10] Colony-stimulating factor-1 increases osteoclast intracellular pH and promotes survival via the electroneutral Na/HCO3 cotransporter NBCn1 [J].

Bouyer, Patrice ;

Sakai, Hiroaki ;

Itokawa, Takashi ;

Kawano, Tsutomu ;

Fulton, Christiaan M. ;

Boron, Walter F. ;

Insogna, Karl L. .

ENDOCRINOLOGY, 2007, 148 (02) :831-840

← 1 2 3 4 5 6 7 8 9 10 →